CTBO (Cantabio Pharmaceuticals) Total Liabilities: $2.22 Mil (As of Dec. 2018)


What is Cantabio Pharmaceuticals Total Liabilities?

Cantabio Pharmaceuticals CTBO Total Liabilities is $2.22 Mil as of Dec. 2018.

Cantabio Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2018 was $2.22 Mil.

Cantabio Pharmaceuticals's quarterly Total Liabilities declined from Jun. 2018 ($2.49 Mil) to Sep. 2018 ($2.44 Mil) and declined from Sep. 2018 ($2.44 Mil) to Dec. 2018 ($2.22 Mil).

Cantabio Pharmaceuticals's annual Total Liabilities increased from Mar. 2016 ($0.42 Mil) to Mar. 2017 ($0.89 Mil) and increased from Mar. 2017 ($0.89 Mil) to Mar. 2018 ($1.98 Mil).

Cantabio Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals Total Liabilities Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Total Liabilities
Get a 7-Day Free Trial 0.01 0.22 0.42 0.89 1.98

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.83 1.98 2.49 2.44 2.22

Cantabio Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cantabio Pharmaceuticals's Total Liabilities for the fiscal year that ended in Mar. 2018 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.983+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.98

Total Liabilities=Total Assets (A: Mar. 2018 )-Total Equity (A: Mar. 2018 )
=0.109--1.873
=1.98

Cantabio Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2018 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.215+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.22

Total Liabilities=Total Assets (Q: Dec. 2018 )-Total Equity (Q: Dec. 2018 )
=0.326--1.889
=2.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $2.22 Mil mean?
Cantabio Pharmaceuticals (CTBO) has a Total Liabilities of $2.22 Mil as of Dec. 2018. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' Total Liabilities too high?
Cantabio Pharmaceuticals' current Total Liabilities is $2.22 Mil.
How does Cantabio Pharmaceuticals' Total Liabilities compare to TNTY and ETNI?
Cantabio Pharmaceuticals' Total Liabilities of $2.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current Total Liabilities is $2.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current Total Liabilities of $2.22 Mil. The current Total Liabilities is $2.22 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current Total Liabilities is $2.22 Mil as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.